Proinflammatory mediators and pathways

Proinflammatory mediators and pathways represent a broad category of biological components and signaling sequences that drive the inflammatory response in the human body. This group includes secreted proteins like cytokines (e.g., Tumor Necrosis Factor-alpha, Interleukin-6) and chemokines, as well as lipid-derived mediators like prostaglandins and leukotrienes (StatPearls, 2023). These molecules activate specific intracellular pathways, such as the NF-kappaB and JAK-STAT cascades, which regulate the expression of genes involved in cell recruitment, activation, and survival (PubMed, PMC4056285). In a healthy state, these pathways are crucial for eliminating pathogens and initiating wound healing; however, their chronic or excessive activation is a hallmark of diseases such as rheumatoid arthritis, inflammatory bowel disease, and atherosclerosis (NIH, 2022). Pharmacological intervention typically involves the use of monoclonal antibodies to neutralize specific mediators or small molecules to inhibit key enzymes and kinases (Nature Reviews Drug Discovery, 2017). Because these pathways are fundamental to immune surveillance, therapeutic targeting requires a balance between reducing pathological inflammation and maintaining the host's ability to fight infections.

Other names

Inflammatory mediatorsPro-inflammatory signalingInflammatory cytokines and pathwaysMediators of inflammation

Therapeutic intervention involves the neutralization of specific cytokines, inhibition of signaling kinases (e.g., JAKs), blockade of enzymatic activity (e.g., COX-2), or modulation of gene transcription to suppress the inflammatory response.